LOGIN  |  REGISTER
Amneal Pharmaceuticals

LifeMD to Participate in Two Investor Conferences During June

June 09, 2025 | Last Trade: US$6.79 0.35 5.43

NEW YORK, June 09, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced that management will be participating in the following investor conferences during the month of June:

  • BTIG Obesity Health Forum, June 18. Management will participate in a virtual panel discussion titled “Direct to Consumer vs. Direct to Enterprise” at 2:00 p.m. Eastern time. Institutional investors can register for the conference by contacting their BTIG representative or by clicking here.

  • Truist Securities Healthcare Disruptors & Digital Health Conference, June 24-25 at the Park Lane Hotel in New York City. Management will participate in a panel discussion titled “Tailored Approach to Weight Loss Solutions” on Tuesday, June 24 at 10:30 a.m. Eastern time and will be available for one-on-one meetings. Institutional investors interested in attending the conference and meeting with LifeMD management should contact their Truist Securities representative.

About LifeMD, Inc.

LifeMD® is a leading provider of virtual primary care. LifeMD offers telemedicine, access to laboratory and pharmacy services, and specialized treatment across more than 200 conditions, including primary care, men’s and women’s health, weight management, and hormone therapy. The Company leverages a vertically integrated, proprietary digital care platform, a 50-state affiliated medical group, a 22,500-square-foot affiliated pharmacy, and a U.S.-based patient care center to increase access to high-quality and affordable care. For more information, please visit LifeMD.com.

Investor Contact
Marc Benathen, Chief Financial Officer
This email address is being protected from spambots. You need JavaScript enabled to view it.

Media Contact
Jessica Friedeman, Chief Marketing Officer
This email address is being protected from spambots. You need JavaScript enabled to view it.

Stock Quote

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page